Martinez Bueno A, Molina MA, Fielding A, et al. Disruptive mutations in TP53 associate with survival benefit in a PARPi trial in ovarian cancer. ESMO 2017, abstract LBA42.
Whole-omics modellen voorspellen de respons op enzalutamide en abirateron bij patiënten met mCRPC
nov 2023 | Uro-oncologie